on June 5, 2013 |
Permalink
| Comments (1)
Topics: Cardiovascular, Service Lines, Business Development, Strategy, Technology Assessment, Planning, Service Line Growth, Volume Growth
Brian Contos and Megan Tooley, Cardiovascular Roundtable
On behalf of the Cardiovascular Roundtable, we are excited to share early results from our analysis of transcatheter aortic valve replacement (TAVR) cases from the just-released Medicare claims data for the 2012 fiscal year (Oct. 1, 2011 – Sept. 30, 2012). To the best of our knowledge, ours is the first analysis of all U.S. TAVR procedures performed in the year following FDA approval.
These analyses address a number of questions we’ve received from members regarding the TAVR marketplace and experiences from early adopters, including volumes, patient characteristics, clinical outcomes, and reimbursement.
Continue reading:
New transcatheter valve benchmarks you won't find anywhere else
on February 13, 2013 |
Permalink
Topics: Cardiovascular, Service Lines, Imaging, Service Line Growth, Volume Growth, Strategy, Referral Management, Physician Issues, Quality, Performance Improvement, Physician Marketing, Marketing
Megan Tooley, Cardiovascular Roundtable
Recently, members have been asking us for strategies to strengthen their relationships with referring physicians, particularly for CV diagnostic testing. In light of declining volumes for CV services, it’s crucial to make sure you are capturing referrals for these front-end services.
We offer many best practices for enhancing CV market capture in our ongoing national meeting presentation "CV Imaging as the Nexus of Growth" and our study CV Marketing Strategy. But today I want to highlight another organization that is strategically marketing a new service that ensures CV imaging report quality to strengthen high-priority referral relationships.
Continue reading:
Here's one idea for securing CV imaging referrals
on January 14, 2013 |
Permalink
Topics: Cardiovascular, Service Lines, Cardiac Cath, Cardiac Surgery, Regionalization and Networks, Strategy, Service Line Growth, Volume Growth, Technology Assessment, Planning, Program Infrastructure, Business Development
Megan Tooley, Cardiovascular Roundtable
There is no question the emergence of transcatheter valve technologies—specifically transcatheter aortic valve replacement (TAVR)—has elicited unprecedented excitement from the cardiovascular community in recent years. However, despite this enthusiasm, the reality is only a portion of hospitals will meet the strict resource and volume requirements necessary to become TAVR sites in the near future.
This may leave many of you wondering, “So what if we’re not a TAVR program? Is there still a place for us in the valve market?” You’re not alone, and as we explore in our national meeting series, your options for treating valve disease and disorders do not end at TAVR.
Learn how one Roundtable member is ensuring their patients have access to a full range of valve services—even if they’re not the TAVR program.
Continue reading:
So you're not a TAVR program—Now what?